首页> 外文期刊>Journal of Molecular Modeling >Identification of old drugs as potential inhibitors of HIV-1 integrase – human LEDGF/p75 interaction via molecular docking
【24h】

Identification of old drugs as potential inhibitors of HIV-1 integrase – human LEDGF/p75 interaction via molecular docking

机译:确定旧药物可作为HIV-1整合酶的潜在抑制剂–通过分子对接的人类LEDGF / p75相互作用

获取原文
获取原文并翻译 | 示例
           

摘要

Integration of viral-DNA into host chromosome mediated by the viral protein HIV-1 integrase (IN) is an essential step in the HIV-1 life cycle. In this process, human protein Lens epithelium-derived growth factor (LEDGF/p75) is discovered to function as a cellular co-factor for integration. LEDGF/p75-HIV-1 IN interaction represents an attractive target for anti-HIV therapy. In this study, approved drugs were investigated for the finding of potential inhibitors on this target. Via molecular docking against the LEDGF/p75-binding pocket of HIV-1 IN, 26 old drugs were selected from the DrugBank and purchased for bioassays. Among them, eight, namely Atorvastatin, Bumetanide, Candesartan, Carbidopa, Diclofenac, Diflunisal, Eprosartan, and Sulindac, were identified as potential inhibitors of LEDGF/p75- HIV-1 IN interaction, whose IC50 values ranged from 6.5 μM to 36.8 μM. In addition, Atorvastatin was previously reported to block HIV-1 replication and may have an important implication for the treatment of AIDS. Our results suggested a mechanism of action for the anti-HIV effects of Atorvastatin. This work provides a new example of inhibitors targeting protein-protein interaction and confirmed that old drugs were valuable sources for antiviral drug discovery.
机译:由病毒蛋白HIV-1整合酶(IN)介导的病毒DNA整合入宿主染色体是HIV-1生命周期中必不可少的一步。在此过程中,人类蛋白镜头上皮衍生的生长因子(LEDGF / p75)被发现充当整合的细胞辅助因子。 LEDGF / p75-HIV-1 IN相互作用代表了抗HIV治疗的诱人靶标。在这项研究中,对批准的药物进行了研究,以寻找针对该靶标的潜在抑制剂。通过与HIV-1 IN的LEDGF / p75结合口袋的分子对接,从DrugBank中选择了26种旧药物并进行了生物测定。其中,阿托伐他汀,布美他尼,坎地沙坦,卡比多巴,双氯芬酸,双氟尼沙尔,依普罗沙坦和舒林酸被确定为LEDGF / p75-HIV-1 IN相互作用的潜在抑制剂,其IC50值为6.5μM。至36.8μM。此外,以前曾报道阿托伐他汀可阻断HIV-1复制,并且可能对艾滋病的治疗具有重要意义。我们的结果提示了阿托伐他汀抗HIV作用的作用机制。这项工作提供了针对蛋白质-蛋白质相互作用的抑制剂的新实例,并证实了旧药物是发现抗病毒药物的宝贵来源。

著录项

  • 来源
    《Journal of Molecular Modeling》 |2012年第12期|p.4995-5003|共9页
  • 作者单位

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China;

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China;

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China;

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China;

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China;

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China;

    State Key Laboratory of Drug Research, Shanghai Institute of Materia Medic;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Drug repositioning; HIV-1 Integrase; Human LEDGF/p75 protein; Molecular docking; Protein-protein interaction;

    机译:药物重新定位;HIV-1整合酶;人类LEDGF / p75蛋白;分子对接;蛋白-蛋白相互作用;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号